Article: Intermediate-term results of repair of congenital heart diseases using pulmonary homografts

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleIntermediate-term results of repair of congenital heart diseases using pulmonary homografts
AuthorsLun, KS1
Chiu, CSW1
Yung, TC1
Cheung, YF1
Cheng, LC1
Chau, AKT1
KeywordsCardiac Operation
Congenital Heart Diseases
Homograft
Issue Date2005
PublisherMedcom Limited. The Journal's web site is located at http://www.hkjpaed.org/index.asp
CitationHong Kong Journal Of Paediatrics, 2005, v. 10 n. 4, p. 271-281+313 [How to Cite?]
AbstractObjective: We evaluate our intermediate-term results of our patients who had insertion of homografts for repair of their congenital heart diseases since the first application in April 1999. Background: Use of homograft valve in the repair of complex congenital heart lesions has been a standard for over two decades. However, homograft is not available locally because of lack of donor. Since 1999, we were able to obtain limited supply of homograft from England. Methods: Between 26 April 1999 and 28 February 2005, 45 patients had insertion of homografts for repair of congenital heart disease. The mean age of operation was 7.2±6.2 years (33 days-28 years). The mean follow-up duration was 32.5±20.6 months (0.03-71 months). The follow-up clinical status was reviewed. Overall survival and freedom from reoperation due to conduit failure were estimated by Kaplan-Meier method. Homograft valve stenosis or regurgitation was assessed by serial echocardiography and cardiac catheterisation. Results: There were one early death (2.2%) and two late deaths (4.4%). One of the late deaths died from non-cardiac cause due to severe bronchial stenosis. The actuarial survival was 93% at 71 months. Of the 42 survivors, majority had improved functional status significantly. There were 40 patients (95%) in NYHA class I or II. Three patients (6.7%) required reoperation for conduit failure. The freedom from reoperation was 85% at 71 months. One patient is awaiting reoperation for severe pulmonary homograft and aortic (truncal) regurgitation. Homograft conduit function of the remaining patients was satisfactory on follow-up. Conclusion: This study showed satisfactory intermediate-term outcome in patients after cardiac operations using homograft.
ISSN1013-9923
2011 Impact Factor: 0.027
2011 SCImago Journal Rankings: 0.029
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorLun, KS
dc.contributor.authorChiu, CSW
dc.contributor.authorYung, TC
dc.contributor.authorCheung, YF
dc.contributor.authorCheng, LC
dc.contributor.authorChau, AKT
dc.date.accessioned2012-10-30T06:07:45Z
dc.date.available2012-10-30T06:07:45Z
dc.date.issued2005
dc.description.abstractObjective: We evaluate our intermediate-term results of our patients who had insertion of homografts for repair of their congenital heart diseases since the first application in April 1999. Background: Use of homograft valve in the repair of complex congenital heart lesions has been a standard for over two decades. However, homograft is not available locally because of lack of donor. Since 1999, we were able to obtain limited supply of homograft from England. Methods: Between 26 April 1999 and 28 February 2005, 45 patients had insertion of homografts for repair of congenital heart disease. The mean age of operation was 7.2±6.2 years (33 days-28 years). The mean follow-up duration was 32.5±20.6 months (0.03-71 months). The follow-up clinical status was reviewed. Overall survival and freedom from reoperation due to conduit failure were estimated by Kaplan-Meier method. Homograft valve stenosis or regurgitation was assessed by serial echocardiography and cardiac catheterisation. Results: There were one early death (2.2%) and two late deaths (4.4%). One of the late deaths died from non-cardiac cause due to severe bronchial stenosis. The actuarial survival was 93% at 71 months. Of the 42 survivors, majority had improved functional status significantly. There were 40 patients (95%) in NYHA class I or II. Three patients (6.7%) required reoperation for conduit failure. The freedom from reoperation was 85% at 71 months. One patient is awaiting reoperation for severe pulmonary homograft and aortic (truncal) regurgitation. Homograft conduit function of the remaining patients was satisfactory on follow-up. Conclusion: This study showed satisfactory intermediate-term outcome in patients after cardiac operations using homograft.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationHong Kong Journal Of Paediatrics, 2005, v. 10 n. 4, p. 271-281+313 [How to Cite?]
dc.identifier.epage281+313
dc.identifier.issn1013-9923
2011 Impact Factor: 0.027
2011 SCImago Journal Rankings: 0.029
dc.identifier.issue4
dc.identifier.scopuseid_2-s2.0-27644517729
dc.identifier.spage271
dc.identifier.urihttp://hdl.handle.net/10722/170355
dc.identifier.volume10
dc.languageeng
dc.publisherMedcom Limited. The Journal's web site is located at http://www.hkjpaed.org/index.asp
dc.publisher.placeHong Kong
dc.relation.ispartofHong Kong Journal of Paediatrics
dc.relation.referencesReferences in Scopus
dc.subjectCardiac Operation
dc.subjectCongenital Heart Diseases
dc.subjectHomograft
dc.titleIntermediate-term results of repair of congenital heart diseases using pulmonary homografts
dc.typeArticle
Author Affiliations
  1. Grantham Hospital Hong Kong